What is Milestone Pharmaceuticals's market cap?

Milestone Pharmaceuticals (MIST) has a market capitalization of $110.7M and trades on NASDAQ.

Who are Milestone Pharmaceuticals's competitors?

Milestone Pharmaceuticals's key competitors include Pfizer, Medtronic plc, Amphastar Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.

Who does Milestone Pharmaceuticals partner with?

Milestone Pharmaceuticals's notable partners include Corxel, Apple.

Where is Milestone Pharmaceuticals headquartered?

Milestone Pharmaceuticals is headquartered in Canada and employs approximately 47 people. It has been publicly traded since 2019.

Milestone Pharmaceuticals (MIST) Stock Fundamentals

Milestone Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative cardiovascular medicines.

Market cap

$110.7M-32.9%

Earnings

Q2 2026 report

August 12, 2026

Revenue$559.0KMiss by $257.7K EPS-$0.21Miss by $0.01

Read the full report

Next report

Nov 11, 2026 (in 2 months)

Revenue estimate$1.1M

EPS estimate-$0.20

Competitors

By market cap

Pfizer$156.51B+14.5%

Medtronic$118.45B-2.4%

Boston Scientific$63.6B-56.4%

Tenet Healthcare$21.4B+32.0%

Mineralys Therapeutics, Inc.$2.4B-15.8%

AMP

Amphastar Pharmaceuticals$1.0B-18.8%

Inhibikase Therapeutics, Inc.$322.3M+177%

Milestone Pharmaceuticals$110.7M-32.9%

By revenue growth

Boston Scientific+13.5%

Medtronic+9.8%

Tenet Healthcare+5.4%

AMP

Amphastar Pharmaceuticals+1.0%

Pfizer-0.2%

By net margin

Boston Scientific17.48%+4.0pp

Pfizer15.65%+1.6pp

Tenet Healthcare14.55%+3.0pp

Medtronic13.93%+0.3pp

AMP

Amphastar Pharmaceuticals10.76%-7.9pp

Profile

Milestone Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative cardiovascular medicines. Its primary focus is on patient-administered, rapid-onset treatments for episodic heart conditions, utilizing a proprietary medicinal chemistry approach to create fast-acting calcium channel blockers. The company's lead product is the first FDA-approved self-administered nasal spray designed to terminate acute cardiac episodes outside of a clinical setting.

Competitive position

Milestone holds a first-mover advantage with the only FDA-approved self-administered treatment for PSVT, positioned as a disruptive alternative to emergency department visits and invasive procedures.

GeographiesUnited States, European Union, China

Customer segmentsPatients, Healthcare Providers, Payors

Business modelDrug Developer, Product Commercialization, Licensing and Royalties

SuppliersActive pharmaceutical ingredient (API) manufacturers, Nasal spray device manufacturers, Contract formulation and assembly services, Packaging providers

CustomersThird-party logistics providers, Pharmaceutical wholesalers, Retail pharmacies, Patients with PSVT and AFib-RVR

CountryCanada

Listed2019

Employees47.0

CEOJoseph G. Oliveto

SectorHealthcare

IndustryBiotechnology

Websitemilestonepharma.com

FilingsSEC EDGAR

FAQ

What is Milestone Pharmaceuticals's market cap?: Milestone Pharmaceuticals (MIST) has a market capitalization of $110.7M and trades on NASDAQ.
Who are Milestone Pharmaceuticals's competitors?: Milestone Pharmaceuticals's key competitors include Pfizer, Medtronic plc, Amphastar Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
Who does Milestone Pharmaceuticals partner with?: Milestone Pharmaceuticals's notable partners include Corxel, Apple.
Where is Milestone Pharmaceuticals headquartered?: Milestone Pharmaceuticals is headquartered in Canada and employs approximately 47 people. It has been publicly traded since 2019.